Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19726453rdf:typepubmed:Citationlld:pubmed
pubmed-article:19726453lifeskim:mentionsumls-concept:C0009247lld:lifeskim
pubmed-article:19726453lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:19726453lifeskim:mentionsumls-concept:C1522484lld:lifeskim
pubmed-article:19726453lifeskim:mentionsumls-concept:C1964257lld:lifeskim
pubmed-article:19726453lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:19726453lifeskim:mentionsumls-concept:C1527249lld:lifeskim
pubmed-article:19726453lifeskim:mentionsumls-concept:C0036525lld:lifeskim
pubmed-article:19726453lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:19726453lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:19726453pubmed:issue9lld:pubmed
pubmed-article:19726453pubmed:dateCreated2009-9-23lld:pubmed
pubmed-article:19726453pubmed:abstractTextThe Bevacizumab Regimens' Investigation of Treatment Effects (BRiTE) study is a prospective, observational cohort study designed to elucidate safety and effectiveness outcomes associated with bevacizumab combined with chemotherapy as used in clinical practice for first-line treatment of metastatic colorectal cancer (mCRC).lld:pubmed
pubmed-article:19726453pubmed:languageenglld:pubmed
pubmed-article:19726453pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19726453pubmed:citationSubsetIMlld:pubmed
pubmed-article:19726453pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19726453pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19726453pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19726453pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19726453pubmed:statusMEDLINElld:pubmed
pubmed-article:19726453pubmed:monthSeplld:pubmed
pubmed-article:19726453pubmed:issn1549-490Xlld:pubmed
pubmed-article:19726453pubmed:authorpubmed-author:GburGGlld:pubmed
pubmed-article:19726453pubmed:authorpubmed-author:BerlinJordanJlld:pubmed
pubmed-article:19726453pubmed:authorpubmed-author:PurdieDavid...lld:pubmed
pubmed-article:19726453pubmed:authorpubmed-author:FlynnPatrick...lld:pubmed
pubmed-article:19726453pubmed:authorpubmed-author:GrotheyAxelAlld:pubmed
pubmed-article:19726453pubmed:authorpubmed-author:KabbinavarFai...lld:pubmed
pubmed-article:19726453pubmed:authorpubmed-author:YoodMarianne...lld:pubmed
pubmed-article:19726453pubmed:authorpubmed-author:KozloffMarkMlld:pubmed
pubmed-article:19726453pubmed:authorpubmed-author:SugrueMary...lld:pubmed
pubmed-article:19726453pubmed:authorpubmed-author:AshbyMark AMAlld:pubmed
pubmed-article:19726453pubmed:authorpubmed-author:Investigators...lld:pubmed
pubmed-article:19726453pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19726453pubmed:volume14lld:pubmed
pubmed-article:19726453pubmed:ownerNLMlld:pubmed
pubmed-article:19726453pubmed:authorsCompleteYlld:pubmed
pubmed-article:19726453pubmed:pagination862-70lld:pubmed
pubmed-article:19726453pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:meshHeadingpubmed-meshheading:19726453...lld:pubmed
pubmed-article:19726453pubmed:year2009lld:pubmed
pubmed-article:19726453pubmed:articleTitleClinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.lld:pubmed
pubmed-article:19726453pubmed:affiliationIngalls Hospital, Suite 401, Harvey, Illinois 60426, USA. mfkozloff@aol.comlld:pubmed
pubmed-article:19726453pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19726453pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19726453lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19726453lld:pubmed